ArticleObesity surgery2026
Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionApproximately 30% of patients experience recurrent weight gain (RWG) within 2 years after metabolic bariatric surgery (MBS). In this setting, GLP-1 receptor agonists (GLP-1 RA) and endoscopic argon plasma coagulation (APC) can be used. The objective is to evaluate the percentage of total body weight loss (%TWL) with liraglutide 3.0 mg versus APC for patients with ≥ 10% RWG over two years.
methodsRetrospective, single-center study (2018-2022) of patients with RWG after RYGB treated with liraglutide 3.0 mg or APC. Weight trajectories were additionally evaluated using a linear mixed-effects model.
results98 patients (mean age 44.5 ± 10.2 years old) with RWG were included. 43 patients were treated with liraglutide 3.0 mg and 55 with APC. There were no statistically significant differences in pre-MBS BMI nor nadir BMI. Average RWG was 23.6 ± 12.01% (median RWG of 21.4%; IQR 16.5-26.5). Significant differences in %TWL were observed from month 12 onwards (p < 0.01), favoring the GLP-1 RA group. Consistently, a significant Time × Treatment interaction was observed in the mixed-effects model (p < 0.001), indicating different weight-loss trajectories between treatment groups. At 12 and 24 months, average %TWL was 14.84 ± 6.56% and 15.59 ± 6.07%, respectively, in the liraglutide 3.0 mg group, and 9.72 ± 8.02% and 7.03 ± 8.30% in the APC group. As a secondary outcome, approximately 43% of the patients treated with GLP-1 RA and 17% of those treated with APC maintained a BMI < 30 kg/m2 at 24 months follow-up.
conclusionOverall, patients treated with liraglutide 3.0 mg maintained a %TWL of approximately 15% between 12 and 24 months of follow-up, whereas patients treated with APC achieved a mean %TWL below 10% during the same period.
Indexed as
Identifiers
42802300What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.